benzyl (1R,2R)-1-hydroxy-1-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)propan-2-yl-carbamate | 1092467-98-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: benzyl (1R,2R)-1-hydroxy-1-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)propan-2-yl-carbamate
• 英文别名: benzyl (1R,2R)-1-hydroxy-1-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)propan-2-ylcarbamate；benzyl N-[(1R,2R)-1-hydroxy-1-(4-methoxyphenyl)-3-pyrrolidin-1-ylpropan-2-yl]carbamate
• CAS: 1092467-98-5
• 化学式: C₂₂H₂₈N₂O₄
• 分子量: 384.475
• InChiKey: PBWJVPFBFAUPPH-NHCUHLMSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  28
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  71
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  benzyl (1R,2R)-1-hydroxy-1-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)propan-2-yl-carbamate 在 5% Pd(II)/C(eggshell) 盐酸 、 氢气 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以85%的产率得到(1R,2R)-2-amino-1-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)propan-1-ol
  参考文献：
  名称：

  [EN] 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  [FR] INHIBITEURS DE GLUCOSYLCÉRAMIDE SYNTHASE DE TYPE 2-ACYLAMINOPROPOANOL

  摘要：

  用于治疗多囊肾病的化合物由结构式（I）表示：或其药学上可接受的盐。一种药物组合物包括由结构式（I）表示的化合物或其药学上可接受的盐。治疗需要的受试者多囊肾病的方法包括向受试者施用由结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。治疗需要的受试者多囊肾病的方法分别包括向受试者施用由结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。

  公开号：

  WO2010039256A1
• 作为产物：
  描述：

  (R)-benzyl 3-hydroxy-1-(methoxy(methyl)amino)-1-oxopropane-2-ylcarbamate 在 吡啶 、 lithium aluminium tetrahydride 、 2,4,6-三甲基氯苯 、 三氟化硼乙醚 、 magnesium 、 1,2-二溴乙烷 作用下， 以 四氢呋喃 、 甲醇 、 丙酮 为溶剂， 反应 77.5h， 生成 benzyl (1R,2R)-1-hydroxy-1-(4-methoxyphenyl)-3-(pyrrolidin-1-yl)propan-2-yl-carbamate
  参考文献：
  名称：

  Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease

  摘要：

  在一个受试者中治疗从系列中选择的肾小球疾病的方法包括向受试者施用有效量的葡糖鞘氨醇合成酶抑制剂。

  公开号：

  US09481671B2

文献信息

• [EN] 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS<br/>[FR] INHIBITEURS DE GLUCOSYLCÉRAMIDE SYNTHASE DE TYPE 2-ACYLAMINOPROPOANOL
  申请人：GENZYME CORP

  公开号：WO2010039256A1

  公开（公告）日：2010-04-08

  A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  用于治疗多囊肾病的化合物由结构式（I）表示：或其药学上可接受的盐。一种药物组合物包括由结构式（I）表示的化合物或其药学上可接受的盐。治疗需要的受试者多囊肾病的方法包括向受试者施用由结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。治疗需要的受试者多囊肾病的方法分别包括向受试者施用由结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。
• Glucosylceramide Synthase Inhibition For The Treatment Of Collapsing Glomerulopathy And Other Glomerular Disease
  申请人：Ibraghimov-Beskrovnaya Oxana

  公开号：US20110166134A1

  公开（公告）日：2011-07-07

  A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject comprises administering to the subject an effective amount of a glucosylceramide synthase inhibitor.

  一种治疗肾小球疾病的方法，所述肾小球疾病选择自系列包括系膜增生性肾小球肾炎、崩解性肾小球病、增生性狼疮性肾炎、新月体性肾小球肾炎和膜性肾病，该方法包括向患者投予有效量的葡糖鞘氨酸合成酶抑制剂。
• 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors
  申请人：Siegel Craig

  公开号：US20110184021A1

  公开（公告）日：2011-07-28

  A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  用于治疗多囊肾病的化合物由结构式（I）表示，或其药学上可接受的盐。一种制药组合物包括由结构式（I）表示的化合物或其药学上可接受的盐。一种治疗需要的多囊肾病的方法包括向患者施用由结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。分别治疗需要的多囊肾病的方法包括向患者施用由结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。
• 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
  申请人：Genzyme Corporation

  公开号：US08309593B2

  公开（公告）日：2012-11-13

  A compound for use in treating polycystic kidney disease is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating polycystic kidney disease in a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. Methods of treating in polycystic kidney disease in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种用于治疗多囊肾病的化合物由结构式（I）表示：或其药学上可接受的盐。一种制药组合物包括由结构式（I）表示的化合物或其药学上可接受的盐。一种治疗需要的多囊肾病的受试者的方法包括向受试者给予由结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。治疗需要的多囊肾病的方法分别包括向受试者给予由结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。
• 2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS
  申请人：Siegel Craig

  公开号：US20100256216A1

  公开（公告）日：2010-10-07

  A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

  一种化合物由结构式（I）表示，或其药学上可接受的盐。一种药物组合物包括由结构式（I）表示的化合物或其药学上可接受的盐。一种治疗需要的受试者的方法包括向受试者施用结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。该受试者患有2型糖尿病；与糖尿病性肾病相关的肾肥大或增生；Tay-Sachs病；高氏病；或Fabry病。分别降低受试者血浆TNF-α、降低血糖水平、降低糖化血红蛋白水平、抑制葡糖鞘氨醇合成酶和降低糖脂浓度的方法包括向受试者施用结构式（I）表示的化合物或其药学上可接受的盐的治疗有效量。